ReviewCNS & neurological disorders drug targets2026
Current Trends in Management of Migraine: A Review of Current Practice and Recent Advances.
Review in CNS & neurological disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Effect of auricular pressure bean combined with wrist-ankle needle on cognitive function and prognosis in migraine patients with anxiety and depression disorders.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMigraine is a common and debilitating neurological condition marked by recurring headaches and sensory disturbances. Although it poses a significant global health burden, its long-term management remains a challenge. Advances in pathophysiological insights have facilitated the development of more targeted treatment approaches. This review explores current and emerging strategies, including diagnostic methods, risk factors, and both pharmacological and nonpharmacological interventions.
methodsAn extensive literature review was conducted to evaluate both conventional and emerging treatment strategies for migraine. The analysis focused on the various phases of migraine, associated therapeutic options, underlying pathophysiological pathways, and existing treatment gaps. A comparative assessment of mechanisms of action, safety profiles, and treatment limitations was also conducted to identify current challenges and research needs.
resultsThe literature highlights recent advances in both acute and preventive treatments for migraine. Key developments include the increasing use of CGRP antagonists (gepants), monoclonal antibodies, and non-invasive neuromodulation techniques. In addition, several FDA-approved drugs such as amitriptyline, ergotamine, flunarizine, and sumatriptan remain widely used. Novel agents, including topiramate, amiloride, and candesartan, are also being evaluated in clinical trials for their potential in migraine management. DISCUSSIONS: While conventional therapies like triptans, NSAIDs, and lifestyle interventions continue to serve as foundational treatments, the shift toward more personalized and mechanism-based approaches is evident. The integration of targeted therapies and neuromodulation reflects growing recognition of migraine's complex pathophysiology. Personalized care models and the exploration of newer pharmacological agents offer promising avenues for more effective and sustainable longterm management.
conclusionA variety of effective treatments are available for migraine, with choice dependent on severity, frequency, comorbidities, and individual tolerance. Gepants, Triptans, and Nutraceuticals represent a promising advancement in migraine therapy due to their targeted action and improved safety. Personalized treatment approaches are essential for optimal management outcomes.
Indexed as
Identifiers
40947701What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.